Price 2011.
Methods | A cost‐utility analysis based on a Markov model, from a German healthcare provider perspective |
Participants | Patients with moderate to severe COPD |
Interventions | indacaterol versus tiotropium or salmeterol |
Outcomes | FEV1, mortality, exacerbations, cost, ICER |
Notes |